(CAPR) Capricor Therapeutics - Performance 62.6% in 12m
Compare CAPR with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
54.55%
#9 in Group
Rel. Strength
93.06%
#556 in Universe
Total Return 12m
62.56%
#17 in Group
Total Return 5y
470.41%
#4 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -12.58%
(?) Percentile in Group
12m Total Return: CAPR (62.6%) vs XBI (-12.1%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
ABBV NYSE AbbVie |
-19.2% | 9.47% | 151% | 75.1 | 14.6 | 0.38 | -49.6% | -19% |
UTHR NASDAQ United Therapeutics |
-11.7% | 23% | 168% | 11.8 | 10.6 | 1.43 | 83.8% | 78.5% |
HLN NYSE Haleon |
-1.45% | 26.1% | 39.7% | 24.7 | 20.3 | 1.8 | 27.1% | - |
AMGN NASDAQ Amgen |
-10.9% | 9.64% | 39.3% | 38.4 | 14.1 | 0.99 | -18.8% | -20% |
LONN SW Lonza |
-3.29% | 3.72% | 31.6% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
BIM PA Biomerieux |
2.96% | 17.6% | 11.9% | 31.5 | 25.4 | 1.47 | -58.7% | -25.1% |
NBIX NASDAQ Neurocrine Biosciences |
-10.2% | -24.7% | -1.51% | 29.1 | 20.7 | 0.27 | 61.5% | 31.6% |
KMDA NASDAQ Kamada |
-6.62% | 33.3% | -5.06% | 24.3 | 22.8 | 0.91 | 47.7% | 3.93% |
Performance Comparison: CAPR vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for CAPR
Total Return (including Dividends) | CAPR | XBI | S&P 500 |
---|---|---|---|
1 Month | -25.16% | -14.90% | -7.04% |
3 Months | -28.59% | -14.51% | -10.88% |
12 Months | 62.56% | -12.11% | 5.72% |
5 Years | 470.41% | -20.56% | 100.77% |
Trend Score (consistency of price movement) | CAPR | XBI | S&P 500 |
1 Month | -71.9% | -85.2% | -76.1% |
3 Months | -78.4% | -87.6% | -86.4% |
12 Months | 56.0% | -24% | 67.8% |
5 Years | 27.1% | -52.8% | 84.3% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #133 | -12.1% | -19.5% |
3 Month | #103 | -16.5% | -19.9% |
12 Month | #16 | 85.0% | 53.8% |
5 Years | #3 | 618% | 184% |
FAQs
Does CAPR Capricor Therapeutics outperforms the market?
Yes,
over the last 12 months CAPR made 62.56%, while its related Sector, the SPDR S&P Biotech (XBI) made -12.11%.
Over the last 3 months CAPR made -28.59%, while XBI made -14.51%.
Over the last 3 months CAPR made -28.59%, while XBI made -14.51%.
Performance Comparison CAPR vs Indeces and Sectors
CAPR vs. Indices CAPR is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 6.74% | -18.1% | -43.9% | 56.8% |
US NASDAQ 100 | QQQ | 7.23% | -17.3% | -43.8% | 58.9% |
US Dow Jones Industrial 30 | DIA | 4.84% | -20.0% | -45.8% | 55.9% |
German DAX 40 | DAX | -5.76% | -17.1% | -62.4% | 43.3% |
Shanghai Shenzhen CSI 300 | CSI 300 | -0.26% | -17.4% | -48.7% | 54.6% |
Hongkong Hang Seng | HSI | -0.93% | -14.0% | -45.2% | 46.4% |
India NIFTY 50 | INDA | 2.73% | -28.6% | -43.3% | 61.9% |
Brasil Bovespa | EWZ | 2.23% | -18.9% | -44.2% | 73.5% |
CAPR vs. Sectors CAPR is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 6.93% | -17.6% | -52.1% | 49.3% |
Consumer Discretionary | XLY | 8.33% | -18.9% | -46.1% | 55.2% |
Consumer Staples | XLP | 1.48% | -25.1% | -51.5% | 50.1% |
Energy | XLE | 5.78% | -13.2% | -42.8% | 75.4% |
Financial | XLF | 4.03% | -20.3% | -51.8% | 43.2% |
Health Care | XLV | 4.33% | -18.4% | -42.7% | 62.7% |
Industrial | XLI | 4.24% | -19.2% | -43.2% | 58.7% |
Materials | XLB | 3.24% | -17.7% | -36.4% | 70.5% |
Real Estate | XLRE | 0.99% | -20.2% | -43.6% | 48.2% |
Technology | XLK | 7.43% | -15.3% | -37.8% | 65.8% |
Utilities | XLU | 1.22% | -23.1% | -48.1% | 36.2% |
Aerospace & Defense | XAR | 2.08% | -24.6% | -53.3% | 39.4% |
Biotech | XBI | 2.22% | -10.3% | -28.0% | 74.7% |
Homebuilder | XHB | 7.35% | -16.0% | -24.4% | 74.3% |
Retail | XRT | 6.98% | -19.4% | -36.6% | 69.6% |